- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: Example 1 [US20090137530] | MT-1303 | MT1303
Compound class: Synthetic organic
Comment: Amiselimod (MT-1303) is claimed in patent US20090137530 (Compound 1-3 is the hydrochloride used experimentally) as a potential immunomodulatory agent . It is a sphingosine-1-phosphate (SIP) receptor prodrug agonist, similar in action to the approved MS drug fingolimod, but with improved receptor subtype selectivity .
Selective SIP1 receptor agonists are being investigated for immunomodulatory/immunosuppresant action in MS and other autoimmune conditions .
1. Kiuchi M, Marukawa K, Kobayashi N, Sugahara K. (2009)
Amine Compound and Use Thereof for Medical Purposes.
Patent number: US20090137530. Assignee: Mitsubishi Tanabe Pharma Corporation. Priority date: 15/12/2005. Publication date: 28/05/2009.
2. Subei AM, Cohen JA. (2015)
Sphingosine 1-phosphate receptor modulators in multiple sclerosis.
CNS Drugs, 29 (7): 565-75. [PMID:26239599]
3. Sugahara K, Maeda Y, Shimano K, Mogami A, Kataoka H, Ogawa K, Hikida K, Kumagai H, Asayama M, Yamamoto T et al.. (2017)
Amiselimod, a novel sphingosine 1-phosphate receptor-1 modulator, has potent therapeutic efficacy for autoimmune diseases, with low bradycardia risk.
Br. J. Pharmacol., 174 (1): 15-27. [PMID:27714763]